6/9 Venetoclax plus navitoclax RR ALL including T-cell. CR ~ 50%, myelosuppression was important safety finding. Venetoclax combinations are being explored for management of RR ALL. https://t.co/StrhwLEuXT
RT @smbenlazar: Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Le…
RT @smbenlazar: Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Le…
RT @smbenlazar: Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Le…
RT @smbenlazar: Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Le…
RT @smbenlazar: Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Le…
RT @smbenlazar: Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Le…
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma #leusm https://t.co/HHPDjPK4Bn
RT @UChicagoLeuk: #throwback to work investigating venetoclax and navitoclax in R/R ALL with @DrWendyStock as senior author! #leusm https:…
#throwback to work investigating venetoclax and navitoclax in R/R ALL with @DrWendyStock as senior author! #leusm https://t.co/TwY0RPpxwr https://t.co/Ku9XkSTB4X
@BloodAdvances @TimCarll @bdermanmd @myeloidmalig @BloodJournal Day 5: venetoclax + navitoclax in R/R ALL/LBL #leusm -R2PD of nav was 50mg in combo with ven 400mg -47% of pt with neutropenic fever -60% CR rate and 28% of pt went onto allo-HCT or CART http
Small numbers but CR/CRi 75% (9/12) in Paed cohort, 50% mrd neg CR (6/12) and 28% of all were bridged to SCT. Lower CR rate if prior ven exposure https://t.co/1MbVwX1v9K
RT @CD_AACR: From the June issue: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acut…
Targeted inhibition of antiapoptotic BCL2 and BCL-XL with the combination of #venetoclax and #navitoclax with chemotherapy was associated with good response in relapsed/refractory acute lymphoblastic #leukemia (ALL) https://t.co/gDPi0YckIP
From the June issue: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic #Leukemia and Lymphoblastic #Lymphoma. https://t.co/4IpbYitRDT @VinodPullarkat @cityofhope #ClinicalTrial #BCL2 h
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acute #lymphoblasticleukemia or #lymphoblasticlymphoma. Study led by Wendy Stock, MD and colleagues, published in @CD_AACR. #AnswerCancer htt
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acute #lymphoblasticleukemia or #lymphoblasticlymphoma. Study led by Wendy Stock, MD and colleagues, published in @CD_AACR. #AnswerCancer htt
ICYMI in @CD_AACR: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic #Leukemia and Lymphoblastic #Lymphoma @VinodPullarkat @cityofhope #ClinicalTrial #AACR21 https://t.co/aqIAFKTBiY
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
RT @UCCancerCenter: Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acut…
Venetoclax/navitoclax combination improved remission rate in pediatric and adult patients with relapsed/refractory acute #lymphoblasticleukemia or #lymphoblasticlymphoma. Study led by Wendy Stock, MD and colleagues, published in @CD_AACR. #AnswerCancer htt
Interesting combo!
RT @CD_AACR: #ICYMI: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblast…
#ICYMI: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic #Leukemia and Lymphoblastic #Lymphoma. @VinodPullarkat @cityofhope #ClinicalTrial #BCL2 https://t.co/OeR0S11rvx https://t.co/R
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma https://t.co/EL9sM5alUg
RT @NatRevClinOncol: In a phase I study of venetoclax + low-dose navitoclax & chemotherapy in pts with R/R ALL or lymphoblastic lymphoma, t…
RT @NatRevClinOncol: In a phase I study of venetoclax + low-dose navitoclax & chemotherapy in pts with R/R ALL or lymphoblastic lymphoma, t…
RT @NatRevClinOncol: In a phase I study of venetoclax + low-dose navitoclax & chemotherapy in pts with R/R ALL or lymphoblastic lymphoma, t…
In a phase I study of venetoclax + low-dose navitoclax & chemotherapy in pts with R/R ALL or lymphoblastic lymphoma, the combination was deemed to be well tolerated. The CR rate was 60%; 28% of pts proceeded to HSCT or CAR T cell therapy on study: http
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma https://t.co/8WQNvaCPSI https://t.co/u2rFcoHwvA
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma #leusm #lymsm https://t.co/3EzYWg8aYx https://t.co/TcX9POJqYf
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. #lymphoma #lymsm https://t.co/KLswUkiG3x
🌟 New this week in @CD_AACR! A Phase I dose-escalation study found that venetoclax with navitoclax and chemotherapy was well tolerated in patients with relapsed or refractory acute lymphoblastic #leukemia and lymphoblastic #lymphoma. https://t.co/ng6bary
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. https://t.co/2OspLKxJWv https://t.co/mXCjRSzHLx
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma https://t.co/wtDSEFSQmw CR 59.6% Undetectable MRD 34% Undetectable MRD 57% in CR/CRi/CRp
RT @ElizSMcKenna: Now online in @CD_AACR: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refract…
Dual combination of Bcl2/xL inhibitors venetoclax and navitoclax along with chemotherapy induce complete molecular remission in one third of patients with multiple relapsed or refractory ALL https://t.co/v7ddiwTYsf
RT @ElizSMcKenna: Now online in @CD_AACR: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refract…
RT @CD_AACR: Just published #OnlineFirst: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refract…
RT @ElizSMcKenna: Now online in @CD_AACR: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refract…
RT @ElizSMcKenna: Now online in @CD_AACR: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refract…
Just published #OnlineFirst: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic #Leukemia and Lymphoblastic #Lymphoma. @VinodPullarkat @cityofhope #ClinicalTrial #BCL2 https://t.co/9SN
Now online in @CD_AACR: #Venetoclax and #Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic #Leukemia and Lymphoblastic #Lymphoma @VinodPullarkat @cityofhope #ClinicalTrial #BCL2 https://t.co/aqIAFKTBiY